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Plan qualityRadiotherapy treatment planning studies contribute significantly to advances and improvements in radi-
ation treatment of cancer patients. They are a pivotal step to support and facilitate the introduction of
novel techniques into clinical practice, or as a first step before clinical trials can be carried out. There have
been numerous examples published in the literature that demonstrated the feasibility of such techniques
as IMRT, VMAT, IMPT, or that compared different treatment methods (e.g. non-coplanar vs coplanar treat-
ment), or investigated planning approaches (e.g. automated planning). However, for a planning study to
generate trustworthy new knowledge and give confidence in applying its findings, then its design, exe-
cution and reporting all need to meet high scientific standards. This paper provides a ‘quality framework’
of recommendations and guidelines that can contribute to the quality of planning studies and resulting
publications. Throughout the text, questions are posed and, if applicable to a specific study and if met,
they can be answered positively in the provided ‘RATING’ score sheet. A normalised weighted-sum score
can then be calculated from the answers as a quality indicator. The score sheet can also be used to suggest
how the quality might be improved, e.g. by focussing on questions with high weight, or by encouraging
consideration of aspects given insufficient attention. Whilst the overall aim of this framework and scoring
system is to improve the scientific quality of treatment planning studies and papers, it might also be used
by reviewers and journal editors to help to evaluate scientific manuscripts reporting planning studies.
 2020 The Author(s). Published by Elsevier B.V. Radiotherapy and Oncology 153 (2020) 67–78 This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Motivation and aim of the RATING framework
Treatment planning has advanced substantially since the intro-
duction of the first computerised treatment planning systems (TPS)
[1,2]. The evolution of computer hard- and software allowed
implementation of advanced algorithms for dose calculation and
optimisation, and facilitated the introduction of many complex
treatment techniques [3–6]. Radiotherapy treatment planning is
currently in an exciting era with novel developments in, for exam-
ple, automated planning, robust planning, online adaptive radio-therapy, knowledge-based planning and plan quality assessment
methods [7–11].
Treatment planning studies serve several purposes. They play
an important role in developing, verifying and implementing
advanced treatment techniques in the clinic [12]. For comparing
treatment techniques, they act as in silico surrogates for clinical
studies, particularly where these are considered not feasible, leav-
ing planning studies as an alternative to investigate the added
value of new approaches. They can also have more technical aims,
e.g. in the development of improved optimisation algorithms and
methods, or the evaluation and comparison of commercial TPS.
Whatever the application, studies should be carefully and robustly
designed and conducted. Also, the work should be reported with
sufficient and consistent detail to ensure: it can be reproduced,
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methods can be safely and reliably applied elsewhere [12].
More generally, treatment planning studies are examples of
computer simulation, which is increasingly popular in many fields
[13]. In most applications, the simulations generated require qual-
ity assurance, via an informal or formal review process that
assesses their credibility or maturity [13], and whether the com-
parison with other simulations, i.e. in this context comparative
plans, is fair. This can be accomplished using credit scores indicat-
ing their trustworthiness. This work aims to enhance treatment
planning study quality by presenting a maturity assessment frame-
work [14] including a numerical scoring (RATING). Background on
the development of this framework is presented in the supplemen-
tary material.
The proposed guidelines are intended to assist investigators to
design, organise and evaluate the quality of a treatment planning
study. They are also aimed at encouraging good practice when
reporting planning studies and could potentially be used by
reviewers and editors to assess consistently the maturity level of
submitted study papers. The guidelines mostly relate to method-
ological aspects of planning studies, i.e. not to other parameters,
e.g. novelty, urgency, relevance of the reported work that might
also determine their potential impact and acceptability to a speci-
fic journal.
Whilst the focus of the guidelines is on planning studies to
answer novel research questions for dissemination to the wider
community, the recommendations can also enhance quality and
reliability of internal studies, e.g. on the safe implementation of a
new treatment technique in the department. To support good prac-
tice in dissemination and reporting, the guidelines are given fol-
lowing the general structure of a scientific manuscript, i.e.
starting with a description of the planning study design and devel-
opment, through to the critical discussion of results and conclu-
sion. Each section addresses issues to be considered in both
developing and reporting a planning study by providing questions
for the researchers to be answered by yes or no, each with a rela-
tive points score. The questions are collected in a checklist. Not all
questions are relevant for all study types, hence such questions can
be selected as applicable/relevant or not and then answered. The
RATING score for the study is then calculated as the normalised
weighted-sum score (as a percentage) of all applicable questions
and can be used to indicate studies carried out and reported within
this proposed high quality framework.
Considerations for designing and developing a planning study:
the introduction section
For designing and developing a study, there should be a clear
reasoning for deciding what is to be studied and why. This will
be reflected in the Introduction section of the final study report,
which should contain various essential parts, including the back-
ground to the study, to help understand its basis and rationale.
The introduction must be concise and end with an unambiguous
study aim defined by research questions which can be concluded
upon at the end of the work.
Given the wide variety of planning study types and scope, for-
mulating the study’s aim should also provide an initial understand-
ing of the type of work presented. An example may be the
comparison of a commercial automated planning solution to a
manual planning technique. Does the study address a scientific
question that is independent of a particular TPS, e.g. quantifying
the dosimetric differences between proton and photon plans? Does
the work contribute to the further development of treatment plan-
ning methodology not yet available in commercial systems, e.g. in-
house algorithm development that is demonstrated for selected
patients?68The study aim formulated by research questions
Any scientific study must have a precisely and concisely defined
aim. Generally, there is a primary research question, possibly sup-
ported by other secondary questions. The research questions
should be limited in number and clearly interconnected and
related to the overall study aim. Research questions should be
defined at the beginning of the formal study; often preceded by
exploratory pilot studies, so appropriate measures can be taken
to ensure a systematic and robust study setup.
1. Does the study have a concise and precise study aim, defined
with a restricted number of interconnected questions? (10
points, mandatory)
The motivation for the research questions
There must be a clinical, technical or scientific need for the
posed research questions, which should be clearly substantiated
in the Introduction section. A thorough literature survey is
required to exclude duplication of already published work and to
identify previously published work that supports the research
questions, pinpointing gaps in current knowledge and understand-
ing, and demonstrating the need for further investigation. This may
include studies that have investigated similar or the same research
questions, e.g. using different scientific approaches. All such rele-
vant work should be concisely discussed and referenced.
2. Has relevant up to date literature been included to support the
need for the current study? (5 points, mandatory)
3. Does the study address an existing knowledge gap? (10 points,
mandatory)
Considerations for the methodology: the Materials and
methods section
Two main aspects should be considered regarding the applied
methodology: firstly, it is crucial that the global study design and
applied methodology will indeed result in answers to the posed
research questions; secondly, in reporting there should be suffi-
cient information for independent researchers to be able to inter-
pret results and reproduce the study in their institutes. In a
manuscript, this will be reflected in the Materials and Methods
section, which should clearly and unambiguously describe how
the work has been done. The following subsections give guidance
on considerations necessary when developing the methodology
and reporting it.
4. Is the global study design adequate for answering the posed
research questions? (10 points, mandatory)
5. Is the global study design described in sufficient detail for
others to interpret and reproduce the results? (5 points,
mandatory)
Patient cohort
The patient cohort is often the foundation of the planning study
and should be described in sufficient detail to provide an under-
standing of how generalisable the study is, e.g. to a local patient
cohort. The selection criteria used for inclusion and exclusion of
patients should be detailed to allow readers to understand if the
planning study would fit their cohorts. The number of included
patients should be stated and should be justified.
The patient cohort size should be carefully considered to ensure
that sufficient patient anatomies and target sizes and locations are
represented. The most appropriate method of patient selection
depends on the research question. Some studies require a large
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adequately, whilst others benefit from a detailed and insightful
analysis of a few representative hand-selected patients. For some
rare indications, large patient cohorts might not even be available.
As for other studies in medicine, also for treatment planning
studies, there may be a need for approval by an institutional
review board or ethics committee. A statement saying that
approval was obtained, or that a request for approval was not
needed, should be included in the manuscript.
6. Are the inclusion and exclusion criteria of the patient cohort
described? (1 point)
7. Is the clinical patient information of the cohort presented,
including disease type, site(s) and clinical staging? (1 point)
8. Is the included number of patients stated, explained and justi-
fied? (1 point)
9. Has there been consideration of the need for ethical and/or legal
approval for the study and if needed, is there a statement about
this? (5 points)
Imaging procedures
Where relevant for the study, the patient imaging and immobi-
lization methods should be described,
10. Have the scanning parameters been reported in sufficient
detail (image modalities, equipment model, slice thickness,
voxel size, patient position (e.g. head first, supine, etc.)? (1
point)
11. Has the applied immobilisation equipment been described,
(e.g. vendor and type, standard settings, etc.)? (1 point)
Treatment machine and settings
Often, the treatment machine and its settings and calibration
need to be described in planning studies, which should include
manufacturer and model, energies used, MLCs, etc. An often
applied metric is the monitor unit (MU). However, this may have
limited value without clear definition; if the reference conditions
are not defined there can easily be a 20% difference in MU depend-
ing on the calibration procedure.
12. Have the treatment machine and relevant parameters been
described with sufficient detail (model, beam energy, MLC,
etc.)? (1 point)
13. Have the MU reference conditions been defined? (1 point)
Definition of targets and OARs
If available, published protocols may be useful to establish GTVs
(gross tumour volume), CTVs (clinical target volume), OARs (or-
gans at risk), PTVs (planning target volume) and PRVs (planning
risk volume) in planning studies to more easily apply results in
other departments. In any case, sufficient detail should be provided
on how the structures were defined including optimisation help
structures, with a focus on their extent and sizes (e.g. mean PTV
volume with a range). Depending on the study type, it may also
be valuable to describe the roles of all involved personnel (RTT,
physicist, oncologist, radiologist, etc.). Details of the contouring
tools used can also be beneficial; auto-contouring with or without
editing, applied software package including version, independent
validation of contours, etc.GTVs and CTVs
For GTV definition, a description of the applied (multi-modality)
imaging is generally needed. For CTV definition around a GTV, the69applied protocol and resulting margins should be summarised. For
the definition of elective CTVs, it should be clear what nodal
regions are included.
14. Has GTV definition been described in sufficient detail, with
references if possible? (1 point)
15. Has CTV definition been described in sufficient detail, with
references if possible? (1 point)
PTVs
For PTVs, applied margins should be specified, along with their
basis, e.g. literature, national protocol, institutionally derived. If
probabilistic/robust planning is used with no PTV definition, then
this should be clearly stated.
16. Has the establishment of PTVs (or alternatively robustness
settings) been described in sufficient detail? (1 point)
17. Have PTV sizes in the patient cohort been described? (1
point)
OARs and PRVs
Non-trivial aspects of OAR definitions relevant for planning or
reporting of NTCP values should be explicitly given, e.g. the con-
toured length of rectum, esophagus or spinal cord, or contouring
of the pharyngeal constrictor muscles if they overlay the GTV, or
whether esophagus contouring considers the position in all phases
of a 4DCT-scan. Reported NTCP predictions almost always rely on
dose metrics directly connected to OAR definitions and should
therefore preferably follow the definition used in the NTCP-
modelling. If applied, margins around OARs to derive PRVs should
be described.
18. Have OAR definitions been described in sufficient detail,
with references if possible? (1 point)
19. Have PRV margins been described in sufficient detail, with
references if available? (1 point)
Treatment planning system and dose calculation
Depending on the planning study type, relevant TPS informa-
tion should be provided in sufficient detail. Different TPS versions
can impact on the options available and are therefore important for
reproducing the results or for clinical implementation. All relevant
user settings should be reported since these often are key to a suc-
cessful implementation, i.e. accelerator, beams, dose grid, optimi-
sation grid, control point spacing etc. If plans from different TPSs
are compared in the study, they should preferentially be compared
in the same software with a common dose sampling and evalua-
tion. This is especially important when small volumes are evalu-
ated [15].
20. Have all applied dose calculation algorithms been described
in sufficient detail? (1 point)
21. For any commercial software used, have the manufacturer,
algorithms and specific versions been stated? (1 point)
22. Have all relevant user parameters and settings in the TPS
been reported, e.g. beams, dose grid, control point spacing?
(1 point)
23. Have all volumes been evaluated with the same software/
methodology? (1 point)
Planning aims and optimisation
A clear description of the planning aims and optimisation
approach is essential, i.e. how an optimal plan should be and
how it was generated. Important to note here is that cost functions
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the functions defining the true or clinical planning aims. This
may, for example, happen if a cost function used in the planning
protocol is not available in the TPS, or if a surrogate convex func-
tion is preferred for planning instead of the non-convex function
used in the protocol, to avoid getting trapped in a local minimum.
Of major importance is a clear description of the applied dose
prescription; dose to the isocentre, to the isodose including 98%
of the PTV volume, etc. It is also important to discriminate between
hard constraints that render a plan unacceptable if violated, and
objectives that should be achieved as well as possible, but without
causing a violation of imposed hard constraints. Objectives are
generally not equally important, i.e. in plan generation, they have
different rankings or priorities, which in many TPS may translate
to differences in weights of cost functions. For example, sparing
of one OAR may be more important than another, or reduction of
small volumes with high dose in an OAR may be more important
than reduction of the mean dose. Therefore, both plan acceptability
and plan quality should be well described as they drive the optimi-
sation. Differences in priorities can often significantly influence the
planning outcome.
Objectives do not always have specified goal values, e.g. for high
or low dose conformality, or dose homogeneity in the PTVs (e.g. in
SBRT). If there are goal values, they are sometimes called soft con-
straints. In the latter case, one planning aim is to meet all soft con-
straints. However, violation of a soft constraint does not
necessarily make a plan unacceptable for patient treatment (see
below, ‘Plan acceptability – minor and major protocol deviations’).
Both for hard and soft constraints, it is good practice to try to
reduce dose to below the constraint level. Also for this, there
may be priorities.
Planning studies need a description of the optimisation
approach, including all aspects that influence final dose distribu-
tions, including the use of the defined priorities/ranking of all
objectives, manual or automated planning, applied optimisation
structures, applied number of iterations, etc. For some planning
studies, it can be useful if the planning aims and applied optimisa-
tion approach align with a published planning protocol (e.g.
DAHANCA, RTOG), defining requirements for target and OARs and
mutual ranking.
24. Are clear planning aims defined, including imposed hard
constraints and planning objectives (with or without soft
constraints)? (5 points, mandatory)
25. Has the ranking of planning objectives (priorities) been
described? (5 points, mandatory)
26. Is the dose prescription clearly defined? (10 points,
mandatory)
27. Is there a description of the applied optimisation process,
including the handling of all objectives with their ranking?
(5 points, mandatory)
28. If manual intervention during or after optimisation is
allowed, has this been described? (1 point)
Bias mitigation
Planning studies comparing treatment or planning approaches
are prone to bias, which can result in incorrect answers to the
research questions. Whether or not there is bias can depend on
the planning study type. If TPS for conventional trial-and-error
planning is mutually compared, it is important that the planner
is as experienced for each TPS used. In the comparison of automatic
vs. manual planning, the retrospective inclusion of recent manual
plans to compare with autoplans does not lead to bias if the
research aim was to compare autoplanning with routine manual70planning, i.e. comparison with not necessarily the best possible
manual planning. If the aim was to compare with the best possible
manual planning, then prospective planning by the best planner in
the best conditions would be a better alternative, or even better,
independent planning by a group of best planners. In treatment
technique comparisons, using retrospectively included plans for
one technique vs. prospective planning for another is likely to
introduce unacceptable bias. In particular, in studies evaluating
technical development, it can be problematic to use clinical plans
as the baseline, since these potentially have numerous compro-
mises (e.g. related to available planning time), and may therefore
not be representative of the true strengths of the conventional
technique. If several delivery techniques (e.g. coplanar and non-
coplanar treatment) are compared with different TPSs with differ-
ent levels of sophistication, there is a clear bias in the technique
comparison. However, if several TPSs of variable sophistication
are used, the planning study may still answer a relevant clinical
question, e.g. in case one of the techniques has its own dedicated
TPS. Serious bias can also be introduced where alternative plans
for patients are generated while having knowledge of the original
plans, or if planning times for one group of plans are clearly longer
than for a competitive group of plans.
29. Have enough study details been provided such that bias
issues could be noted? (5 points, mandatory)
30. Has bias been sufficiently mitigated to reliably answer the
posed research question? (10 points, mandatory)
Plan acceptability – minor and major protocol deviations
Plan acceptability, i.e. the suitability of generated dose distribu-
tions for clinical treatment, is generally of high importance in a
planning study. In the planning protocol, there can be definitions
for minor or major protocol deviations (e.g. for a planning study
in the context of a formal clinical study). The outcome of plan
acceptability evaluations, and of minor or major deviations, are
always binary, i.e. yes or no answers. Plan acceptability can be
assessed by comparing achieved plan parameters with imposed
hard constraints. Depending on the study, plans could also become
unacceptable with too many or too large deviations of soft con-
straints (see, ‘Planning aims and optimisation approaches‘). Analy-
sis of plan parameters, to assess plan acceptability and minor and
major deviations, can be supplemented by a formal evaluation of
plans by a clinician for the whole cohort or a subgroup. This is
highly recommended for planning studies with rather clinical
research questions.
31. Was the procedure for assessment of plan acceptability well
described? (1 point)
32. Was the procedure for assessment of minor and major pro-
tocol deviations well described? (1 point)
Plan (re-)normalisation for plan comparisons
For various reasons, it can be useful to (re-)normalise generated
plans before final evaluations or comparisons. For example, where
there are slight variations in PTV coverage between plans, re-
normalisation can ensure that coverage is the same for all involved
plans. Where other PTV dose characteristics are also similar, fur-
ther plan evaluations and comparisons can then focus on OAR
doses. However, it should be noted that (re-)normalisation can
change the optimisation optimum and only small changes are
recommended.
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Dose–volume parameters for plan evaluation and comparison
Plan evaluations and comparisons should always include the
most important plan parameters used for defining the planning
aims (constraints and objectives). As explained in ‘Planning aims
and optimisation’, these parameters may not always be the same
as the obtained values for the cost functions used for plan genera-
tion. Additional parameters may also be used.
34. Have sufficiently comprehensive dose–volume parameters
been used for plan evaluations and comparisons? (5 points,
mandatory)
Population-mean DVHs
Population-mean or median DVHs may provide added value to
planning studies. If used, it is recommended to include confidence
intervals to visualise the significance of differences. How
population-mean DVHs and confidence intervals are derived
should be clearly defined. Statistical comparison of average DVHs
has been described by Bertelsen et al [5].
35. Has the algorithm for creating population-mean/median
DVHs been reported? (1 point)
36. Have the definitions of confidence intervals been included?
(1 point)
Plan evaluations by clinicians
The potential role of clinicians in assessing plan acceptability
has been described above. For many planning studies, formal plan
evaluations or comparisons by clinicians, e.g. using visual analogue
scales [10], can provide important added value regarding the qual-
ity of acceptable plans. Clinicians give an overall assessment of the
plans, including any trade-offs between planning objectives, high
and low dose conformality, etc. Moreover, new techniques or plan-
ning approaches will only be introduced clinically if they are pre-
ferred by treating clinicians. For plan comparisons, blinded
clinician scoring for avoiding bias is recommended [10].
37. Have clinicians scored plans to assess quality? (1 point)
38. Were plan comparisons by clinicians blinded? (1 point)
Predicted tumour control probability and normal tissue complication
probabilities for plan evaluation and comparison
The potential clinical impact of plans can sometimes be esti-
mated using predicted tumour control probabilities (TCP) and/or
predicted normal tissue complication probabilities (NTCP). How-
ever, the underlying models may have large uncertainties. There-
fore, TCPs and NTCPs can generally only be used to complement
other reporting, e.g. on obtained DVH parameters.
39. Have any applied TCP models been described and refer-
enced? (1 point)
40. Have any applied NTCP models been described and refer-
enced? (1 point)
Plan deliverability and complexity
Depending on the study aim, it may be important to verify that
generated plans can indeed be delivered with sufficient accuracy.
The most direct approach for this is by dosimetric measurements
with an appropriate detector, during plan delivery at a treatment
unit. Often the dosimetric analyses are performed with gamma71index analysis [16]. These should be specified in detail, including
specification of local or global gamma index, absolute or relative
comparison, dose difference and distance criteria, dose difference
normalisation point, dose low gradient region, low dose cut-off
[17,18]. The standard and experimental plans should preferentially
be measured in pairs, so that differences in measurement condi-
tions have minimal impact on the two measurements.
In plan comparisons, sometimes plan parameters such as MU,
mean leaf distance, etc. are used to demonstrate that plans gener-
ated with a novel planning technique are not more complex than
those from another conventional planning approach. However,
there is a lack of agreement on the general applicability of pro-
posed plan complexity parameters in terms of prediction of plan
deliverability [19].
41. Have methods used to assess plan deliverability and com-
plexity been described in sufficient detail? (1 point)
Composite plan quality metrics
Composite plan quality metrics, used in commercial products
such as PlanIQ, Mobius, etc. are sometimes used in planning stud-
ies. However, these composite metrics should be clearly motivated
for the specific study (e.g. based on literature), and it should be
clearly specified how they are calculated, considering all planning
aims with their priorities [20,21]. Typically, composite plan quality
metrics should be reported in addition to dose parameters rather
than instead.
42. Is there a sufficient basis (e.g. in the literature) for any
selected composite plan quality metrics? (1 point)
43. Is there an adequate description of the calculation of the
composite plan quality metrics? (1 point)
Planning and delivery times
Efficiency in treatment planning and treatment delivery is often
of high interest in planning studies, complementing the informa-
tion on acceptability, dosimetric plan quality and deliverability.
For treatment planning, a clear distinction between hands-on plan-
ning time and calculation time may be needed. It is important to
detail the applied hardware used. Delivery times can be defined
in various ways, e.g. total beam-on time, total time to deliver the
dose including gantry and/or couch motions, etc. The most direct
way to establish these is by measurement at the treatment unit.
Sometimes delivery times may also be estimated by dedicated pre-
diction algorithms.
44. Has measurement of planning times been described in suffi-
cient detail? (1 point)
45. Has the establishment of delivery times been described in
sufficient detail? (1 point)
Statistical analysis
In planning studies, often (paired) differences in plan parame-
ters are gathered for plans generated with different planning
approaches (e.g. manual vs. automatic planning), or with different
treatment approaches (e.g. photons vs. protons). Depending on the
planning study scope and on the approach to patient selection, sta-
tistical analysis of results may or may not be applicable. Avoiding
meaningless statistics is as important as providing an appropriate
statistical analysis where needed. When patients were hand-
selected, for example, to demonstrate the advantages of a novel
planning technique for patients with specific characteristics, statis-
tical analysis is usually not applicable. When a planning study aims
to conclude on the average performance of planning techniques,
Radiotherapy Treatment plannINg study Guidelines (RATING)patient selection may have to be random and appropriate statisti-
cal testing needs to be performed to assess the statistical signifi-
cance of the results obtained in terms of p-values, confidence
intervals, etc.
In case multiple tests are performed to answer a research ques-
tion, corrections might be applicable to decrease the risk of false
conclusions, i.e. correct for the number of tests or compared sce-
narios. As explained above in ‘Patient cohort’, the number of
patients included in a planning study needs to be explained and
justified. Especially, in case no statistically significant differences
are found between planning approaches or treatment techniques,
it can be informative to calculate the smallest difference which
could be resolved.
46. Have proper statistical methods been used and described in
sufficient detail? (5 points, mandatory)
47. In case of multiple testing for research questions, has this
been handled appropriately? (1 point)
Considerations for reporting the results: the results section
The study produces a range of results that need to be structured,
analysed and evaluated. The reported results should provide suffi-
cient data to answer the posed research questions, leading to the
study’s findings and conclusions. Generally, only a summary of
all the generated data is presented (presenting information instead
of data). The raw data may then be included in supplementary
material, which can provide useful information for detailed analy-
ses by readers. The results should be presented in a structured
coherent way, together, and separate from any discussion or sub-
jective observations.
Generation of appropriate tables and figures is of crucial impor-
tance; they should provide a clear graphical representation of the
results obtained, ideally in a format that conclusions are immedi-
ately clear. However, the figures should not usually be a repetition
of the tables, or vice versa. In the recommendations for the ‘Mate-
rials and Methods’ section, several ways for describing differences
in dosimetric plan parameters, including dose-volume parameters,
population-mean DVHs, and TCPs and NTCPs are described.
48. Does the provided data contribute to (at least partly)
answering all aspects of the research questions, e.g. plan
acceptability, dosimetric quality, deliverability and planning
and delivery times? (10 points, mandatory)
Dose distribution reporting
Although there should be a focus on the research questions, it is
important that there are complete summaries of the characteristics
of the generated dose distributions; in the end, full plans need to
be considered, not only some aspects. For example, if the research
question is about high doses, also information on low doses, con-
formality, etc. as observed in the patient cohort should be pro-
vided. If the research question is on OAR doses, also PTV doses
should be reported, etc. Study-specific dose metrics may have to
be supplemented with more common dose metrics, so compar-
isons can be made with other available reported work. It is often
useful to add data (e.g. dose distributions, DVHs) for an example
patient.
49. Are complete summaries of the dose distributions in the
patient cohort provided (low doses, high doses, OARs, PTV,
patient, etc.)? (5 points, mandatory)
50. Are tables and figures optimised to clearly present the
results obtained? (1 point)7251. Have the answers to the research questions been illustrated
for an example patient by providing dose distributions,
DVHs, etc.? (1 point)
Plan acceptability reporting – minor and major protocol deviations
Plan acceptability should state whether the plan fulfils relevant
protocol requirements, and which parameters are not acceptable if
any. If deviations were acceptable in the study design, this should
be stated in the methods and reported in the results, including any
minor and major protocol deviations.
52. In case of treatment technique or planning technique com-
parisons, was plan acceptability reported separately for each
technique? (1 point)
53. Has plan acceptability been reported in sufficient detail:
how many plans were acceptable, how many were not and
for what reasons (e.g. violation of hard constraints, violation
of soft constraints, other reasons)? (1 point)
54. Was there adequate reporting of minor and major protocol
deviations? (1 point)
Deliverability and complexity reporting
Where deliverability QA measurements are performed, results
should be evaluated with the criteria used in clinical routine. How-
ever, apart from answers of acceptable/not acceptable, numerical
test results should also be provided (e.g. obtained gamma passing
rates, etc.), since the clinical thresholds are only a bare minimum.
Along with the QA measurements, or as an alternative, complexity
parameters like MU, number of segments, mean leaf separation,
etc. may be reported [17].
55. Has the deliverability of the plans been adequately
reported? (1 point)
56. Have plan deliverability and complexity been investigated in
sufficient detail in relation to the posed research questions?
(1 point)
Planning and delivery times reporting
Depending on the study it may be highly relevant to report on
planning and delivery times. If planning or delivery takes too long,
the clinical application may not be feasible. Differences in planning
times for various techniques may indicate a study bias
57. Have planning and delivery times been adequately evalu-
ated and reported? (1 point)
Patient-specific analyses reporting
Planning studies often compare groups of paired plans (e.g. for
each patient a photon and a proton plan) to investigate population-
mean differences with their statistical significance. In addition,
enough detail should be provided for individual patients. For
example, if there is no statistically significant difference for a plan
parameter, there may be clinically significant differences for indi-
vidual patients. These should be explicitly described, as they may
be highly relevant for sub-groups or increasing personalised med-
icine considerations.
It is also important to sufficiently report results for so-called
outlier patients. If they are excluded from population analyses this
needs to be well motivated and explained.
58. Is there sufficient description of inter-patient variations in
the results presented? (1 point)
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from population analyses been sufficiently motivated and
explained? (1 point)
Statistical reporting
If applicable, the statistical reporting for the primary research
question should be clear and stand out, compared to the other sec-
ondary research questions. It is common practice to show one sig-
nificant digit of p-values. Any p-value below 0.001 could be
reported as <0.001. Avoid reporting of p-values above the signifi-
cant threshold as non-significant or NS, i.e. report the numbers.
In addition to p-values, it is advised to also report confidence inter-
vals or equivalent where available since this can be more informa-
tive than p-values.
60. Are the p-values reported appropriately? (1 point)
61. Are there confidence intervals for the appropriate parame-
ters? (1 point)
Considerations for the interpretation and discussion of the
results: the discussion section
The Discussion section often starts with an overall interpreta-
tion by the scientists of the presented results in terms of answers
to the research questions, posed at the initial design stage, as laid
out in the Introduction. After that, the interpretation is put in con-
text (e.g. of other literature) and discussed in terms of limitations,
clinical significance, clinical applicability and future work.
62. Is there an overall interpretation of the data presented in the
Results section as to how the posed research questions are
answered? (10 points, mandatory)
Comparison with literature
Mostly, planning studies are performed where there are some
existing knowledge or knowledge gaps reported in the literature.
There may also be publications describing answers to the posed
research questions using other methodology. The obtained
answers to the research questions should be discussed in the con-
text of the relevant literature.
63. Has the study been sufficiently discussed in the context of
existing literature? (5 points, mandatory)
Clinical and statistical significance
Generally, discussion of the results focusses on statistically sig-
nificant results. However, statistical significance does not mean
that observed differences are clinically meaningful, e.g. in the case
that they are small. Therefore, beyond statistical significance, the
study results also should be discussed in the context of clinical sig-
nificance. This can be done, for example, by referring to literature
results describing the clinical impact of observed differences.
64. Does the discussion focus on statistically significant results?
(1 point)
65. Is the potential clinical significance of the results clearly dis-
cussed (assuming practical application would be feasible)?
(5 points, mandatory)
Clinical applicability of the study results
Clinical applicability can be an important point of discussion. A
description of any limitations (e.g. for selected patients only) or73restrictions (e.g. availability of certain equipment) may be of high
value.
66. Is future clinical applicability sufficiently discussed? (1
point)
Study limitations
Most studies have some limitations in the methods of obtaining
answers and/or in the provided answers to the posed research
questions. These should be clearly addressed in the Discussion sec-
tion. A major limitation may be bias, as described in ‘Considera-
tions for the methodology: the Materials and Methods section’.
67. Has the impact of the study limitations on the provided
answers to the research questions been sufficiently dis-
cussed? (10 points, mandatory)
Future work
In many studies, a description of future work can be highly rel-
evant. This can relate to new ideas for new studies, including those
that could possibly avoid current study limitations, plans for clin-
ical application of the study results, research for different tumour
sites, etc.
68. Has the potential future work arising from the study been
discussed? (1 point)
Considerations for the conclusion from the planning study: the
Conclusion section
The conclusion from any such study should focus on the
answers to the primary research question. Accurate descriptions
with positive and negative observations are needed. The presented
conclusions should be fully supported by the obtained results,
without wider conjecture.
69. Do the presented conclusions represent answers to the
posed research questions? (5 points, mandatory)
70. Are the conclusions supported by the results? (5 points,
mandatory)
71. Are the conclusions a fair summary of all results? (5 points,
mandatory)
Considerations for supplementary sections of published
planning studies: the Supplementary Materials section
Supplementary materials
The data presented in the Results section of the main paper
often only consist of a concise overview of all the (raw) data gen-
erated. This can have several reasons, including raw data having
been processed to optimally answer the research questions, a
specific journal setting a limit on the number of allowed figures
and tables, lack of space in the main body for more detail, etc. In
these cases, an electronic appendix may be added. It should be
noted that this appendix also should meet adequate quality levels
of readability, clarity, coherence, etc., with clear links and support
for the main report. There should be clear descriptions of the pre-
sented data and of the methods used to produce them. Any data
presentation should be guided by the FAIR Data Principles [22].
As much as possible, an electronic appendix has to make sense
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of sufficient relevance? (1 point)
73. Is the presentation of the included information of sufficient
quality, including readability? (1 point)
Sharing data must conform to legal regulations on patient data
confidentiality, which may vary in different jurisdictions. However,
it is possible to publish anonymised data if the applicable regula-
tions are followed. Whilst DICOM CT images, structures, resulting
dose distributions and plans are not commonly published today,74scientists should keep in mind that a planning study’s contribution
to the scientific community is significantly higher if the underlying
data is available. Even where data cannot be made fully publicly
available, it may be possible to indicate a willingness to share data
with other researchers under an appropriate written agreement.
Mostly, it will be possible to share the analysis code.
74. Has sufficient underlying data been made available or a will-
ingness to share data been indicated, within local data shar-
ing restrictions? (5 points, mandatory)
(continued on next page)
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All questions above are collected in the RATING score sheet and
given weights reflecting their relative importance (Table 1 and
Excel spreadsheet in the electronic appendix). The weights are
indicative and constrained to a limited set. Questions can be
selected as Applicable (or Not) to the study, although some are
defined as applicable to all studies, and then answered as Yes, or
left blank if No. The RATING score is the normalised weighted-
sum of all mandatory (blue shading) and applicable ‘Yes’ answers,75having a maximum value of 100%. In the preparation phase of a
planning study, by examining high-weight or insufficiently-
considered issues in the list, the score sheet can assist in ensuring
a high-quality research question, study design and setup; and in
the writing phase of the study, a high-quality report.
75. Is the RATING score added to the manuscript? (5 points,
mandatory)
76. Is the accompanying question table added to the cover letter
or the supplementary material? (1 point)
Radiotherapy Treatment plannINg study Guidelines (RATING)Summary
This ‘RATING’ framework is proposed with the aim of improving
the scientific quality of treatment planning studies and papers
reporting them. It can be used at any stage, from the initial plan-
ning phase to inform the study design, to the end phase to assist
in study evaluation and reporting. It is hoped it will be a76useful and consistent tool for researchers and for reviewers and
editors.Conflict of Interest Statement
There are no conflict of interest in the author group in the cur-
rent RATING project.
All questions from the text are listed. And each is assigned a weight. Most questions can be selected as Relevant/Applicable for the study or not, although some are considered
relevant for all planning studies (marked blue). Questions answers can be Yes (affirmed with a ‘tick’ in the table) or No (leave box blank). From the answers to the Relevant/
Applicable questions, a normalised weighted-sum score, the RATING score, is calculated with a maximum of 100%. The spreadsheet in the supplementary material automates
this. The weights assigned to the questions are indicative. They represent the author group consensus on relative importance but constrained to a limited set of levels.
Different researchers might suggest different specific weights for particular questions in a given context; however, the aim is to have a consistent approach for scoring
without too many levels.
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